Oculis Eyes Opportunities With Fresh Funding and Novartis Licensing Deal

As Novartis looks to move out of much of its ophthalmology research with the forthcoming spinoff of Alcon, fellow Swiss firm Oculis has licensed one of its assets and secured new financing to progress its back-of-the-eye treatments.